Skip to main content
SpringerLink
Log in

Therapie des Typ-1-Diabetes

Kurzfassung der S3-Leitlinie (AWMF-Registernummer: 057–013; 2. Auflage), Stand: 30. Juni 2018

Therapy of type 1 diabetes

Abstract of the S3 guideline (AWMF register number: 057-013; 2nd edition), Status: June 30, 2018

  • DDG Praxisempfehlungen
  • Published:
Der Diabetologe Aims and scope

A Leserbriefe to this article was published on 19 August 2019

A Leserbriefe to this article was published on 19 August 2019

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. American Diabetes Association. 2. Classification and Diagnosis of Diabetes. Diabetes Care 2017; 40 (Suppl. 1): S11–S24. https://doi.org/10.2337/dc17-S005. EK IV

    Article  Google Scholar 

  2. Johnson DD, Palumbo PJ, Chu CP. Diabetic ketoacidosis in a communitybased population. Mayo Clin Proc 1980; 55 (2): 83–88. EK III

    CAS  Google Scholar 

  3. Bottazzo GF, Florin-Christensen A, Doniach D. Islet-cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies. Lancet 1974; 2 (7892): 1279–1283. EK III

    Article  CAS  Google Scholar 

  4. Palmer JP, Asplin CM, Clemons P et al. Insulin antibodies in insulindependent diabetics before insulin treatment. Science 1983; 222 (4630): 1337–1339. EK III

    Article  CAS  Google Scholar 

  5. Wiest-Ladenburger U, Hartmann R, Hartmann U et al. Combined analysis and single-step detection of GAD65 and IA2 autoantibodies in IDDM can replace the histochemical islet cell antibody test. Diabetes 1997;46 (4): 565–571. EK III

    CAS  Google Scholar 

  6. Bingley PJ, Bonifacio E, Mueller PW. Diabetes Antibody Standardization Program: first assay proficiency evaluation. Diabetes 2003; 52 (5):1128–1136. EK III

    CAS  Google Scholar 

  7. Törn C, Mueller PW, Schlosser M et al. Diabetes Antibody Standardization Program: evaluation of assays for autoantibodies to glutamic acid decarboxylase and islet antigen-2. Diabetologia 2008; 51 (5): 846–852. EK III

    Google Scholar 

  8. Schlosser M, Mueller PW, Torn C et al. Diabetes Antibody Standardization Program: evaluation of assays for insulin autoantibodies. Diabetologia 2010; 53 (12): 2611–2620. EK III

    CAS  Google Scholar 

  9. Imagawa A, Hanafusa T, Miyagawa J et al. A novel subtype of type 1 diabetes mellitus characterized by a rapid onset and an absence of diabetes-related antibodies. Osaka IDDM Study Group. N Engl J Med 2000;342 (5): 301–307. EK III

    Article  CAS  Google Scholar 

  10. National Institute for Health and Clinical Excellence. Type 1 diabetes in adults: diagnosis and management. 2015. EK IV

  11. American Diabetes Association. Standards of Medical Care in Diabetes—2017. Diabetes Care 2017; 40 (Suppl. 1). EK IV

    Google Scholar 

  12. DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulindependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329 (14): 977–986. EK Ib

    Google Scholar 

  13. Fanelli CG, Epifano L, Rambotti AM et al. Meticulous prevention of hypoglycemia normalizes the glycemic thresholds and magnitude of most of neuroendocrine responses to, symptoms of, and cognitive function during hypoglycemia in intensively treated patients with short-term IDDM. Diabetes 1993; 42 (11): 1683–1689. EK IIb

    CAS  Google Scholar 

  14. Fritsche A, Stefan N, Haring H et al. Avoidance of hypoglycemia restores hypoglycemia awareness by increasing beta-adrenergic sensitivity in type 1 diabetes. Ann Intern Med 2001; 134 (9): 729–736. EK IIb

    CAS  Google Scholar 

  15. Deutsche Diabetes Gesellschaft. S2k-Leitlinie Diagnostik, Therapie und Verlaufskontrolle des Diabetes mellitus im Alter. Angemeldete Leitlinie in Entstehung. Im Internet: http://www.awmf.org/leitlinien/detail/anmeldung/1/ll/057-017.html. EK IV

  16. Lipska KJ, Hirsch IB, Riddle MC. Human Insulin for Type 2 Diabetes: An Effective, Less-Expensive Option. JAMA 2017; 318 (1): 23–24. https://doi.org/10.1001/jama.2017.6939. EK IV/LoE 4

    Article  PubMed  Google Scholar 

  17. Lucidi P, Porcellati F, Marinelli Andreoli A et al. Pharmacokinetics and Pharmacodynamics of NPH Insulin in Type 1 Diabetes: The Importance of Appropriate Resuspension Before Subcutaneous Injection. Diabetes Care 2015; 38 (12): 2204–2210. https://doi.org/10.2337/dc15-0801. EK IV

    Article  CAS  Google Scholar 

  18. Wutte A, Plank J, Sinner F. Dose-response relationship and within-subject variability of insulin detemir and NPH insulin in subjects with Type 1 diabetes. Diabetes 2004; 53 (Suppl. 2): A152. EK IV

    Google Scholar 

  19. Becker RHA, Frick AD. Clinical pharmacokinetics and pharmacodynamics of insulin glulisine. Clin Pharmacokinet 2008; 47 (1): 7–20. https://doi.org/10.2165/00003088-200847010-00002. EK III

    Article  CAS  PubMed  Google Scholar 

  20. Weyer C, Heise T, Heinemann L. Insulin Aspart in a 30/70 Premixed Formulation. Pharmacodynamic properties of a rapid-acting insulin analog in stable mixture. Diabetes Care 1997; 20 (10): 1612–1614. https://doi.org/10.2337/diacare.20.10.1612. EK III

    Article  CAS  PubMed  Google Scholar 

  21. Woodworth JR, Howey DC, Bowsher RR et al. Comparative pharmacokinetics and glucodynamics of two human insulin mixtures. 70/30 and 50/50 insulin mixtures. Diabetes Care 1994; 17 (5): 366–371. EK II

    CAS  Google Scholar 

  22. Heise T, Hövelmann U, Nosek L et al (2015) Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine. Expert Opin Drug Metab Toxicol. Ek Iii 11(8):1193–1201. https://doi.org/10.1517/17425255.2015.1058779

    Article  CAS  Google Scholar 

  23. Haahr H, Heise T. A review of the pharmacological properties of insulin degludec and their clinical relevance. Clin Pharmacokinet 2014; 53 (9):787–800. https://doi.org/10.1007/s40262-014-0165-y. EK I

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Nosek L, Coester HV, Roepstorff C et al (2014) Glucose-Lowering Effect of Insulin Degludec is Independent of Subcutaneous Injection Region. Clin Drug Investig. Ek Ii 34(9):673–679. https://doi.org/10.1007/s40261-014-0218-x

    Article  CAS  Google Scholar 

  25. Koehler G, Treiber G, Wutte A et al. Pharmacodynamics of the longacting insulin analogues detemir and glargine following single-doses and under steady-state conditions in patients with type 1 diabetes. Diabetes Obes Metab 2014; 16 (1): 57–62. https://doi.org/10.1111/dom.12178. EK II

    Article  CAS  Google Scholar 

  26. Heise T, Pieber TR. Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies. Diabetes Obes Metab 2007; 9 (5): 648–659. https://doi.org/10.1111/j.1463-1326.2007.00756.x. EK I

    Article  CAS  Google Scholar 

  27. Becker RHA, Dahmen R, Bergmann K et al. New insulin glargine 300 Units · mL-1 provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 Units ·mL-1: The ELEMENT 1 study. Diabetes Care 2015; 38 (4): 637–643. https://doi.org/10.2337/dc14-0006. EK II

    Article  CAS  Google Scholar 

  28. Shiramoto M, Eto T, Irie S et al. Single-dose new insulin glargine 300 U/ml provides prolonged, stable glycaemic control in Japanese and European people with type 1 diabetes. Diabetes Obes Metab 2015; 17 (3): 254–260. https://doi.org/10.1111/dom.12415. EK II

    Article  CAS  PubMed  Google Scholar 

  29. Heise T, Pieber TR, Danne T et al. A Pooled Analysis of Clinical Pharmacology Trials Investigating the Pharmacokinetic and Pharmacodynamic Characteristics of Fast-Acting Insulin Aspart in Adults with Type 1 Diabetes. Clin Pharmacokinet 2017; 56 (5): 551–559. https://doi.org/10.1007/s40262-017-0514-8. EK II

    Article  CAS  Google Scholar 

  30. Heise T, Eckers U, Kanc K et al. The pharmacokinetic and pharmacodynamic properties of different formulations of biphasic insulin aspart: A randomized, glucose clamp, crossover study. Diabetes Technol Ther 2008; 10 (6): 479–485. https://doi.org/10.1089/dia.2008.0019. EK II

    Article  CAS  Google Scholar 

  31. Famulla S, Hovelmann U, Fischer A et al. Insulin Injection Into Lipohypertrophic Tissue: Blunted and More Variable Insulin Absorption and Action and Impaired Postprandial Glucose Control. Diabetes Care 2016; 39 (9): 1486–1492. https://doi.org/10.2337/dc16-0610. EK II/LoE

    Article  CAS  Google Scholar 

  32. Heise T, Weyer C, Serwas A et al. Time-Action Profiles of Novel Premixed Preparations of Insulin Lispro and NPL Insulin. Diabetes Care 1998; 21 (5): 800–803. https://doi.org/10.2337/diacare.21.5.800. EK III

    Article  CAS  PubMed  Google Scholar 

  33. Rave K, Heinemann L, Puhl L et al. Premixed formulations of insulin lispro. Activity profiles in type 1 diabetic patients. Diabetes Care 1999; 22 (5): 865–866. EK III

    CAS  Google Scholar 

  34. Brunner M, Pieber T, Korsatko S et al. The Distinct Prandial and Basal Pharmacodynamics of IDegAsp Observed in Younger Adults Are Preserved in Elderly Subjects with Type 1 Diabetes. Drugs Aging 2015; 32 (7): 583–590. https://doi.org/10.1007/s40266-015-0272-y. EK II

    Article  CAS  Google Scholar 

  35. Heise T, Nosek L, Roepstorff C et al. Distinct Prandial and Basal Glucose-Lowering Effects of Insulin Degludec/Insulin Aspart (IDegAsp) at Steady State in Subjects with Type 1 Diabetes Mellitus. Diabetes Ther 2014; 5 (1): 255–265. https://doi.org/10.1007/s13300-014-0070-2. EK II

    Article  CAS  Google Scholar 

  36. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Kurzwirksame Insulinanaloga zur Behandlung des Diabetes mellitus Typ 1. Abschlussbericht. Auftrag A05-02. Version 1.0; 2007.. EK Ia

  37. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Langwirksame Insulinanaloga zur Behandlung des Diabetes mellitus Typ 1. Abschlussbericht. Auftrag A05-01. Version 1.0; 2010.. EK Ia

  38. Singh SR, Ahmad F, Lal A et al. Efficacy and safety of insulin analogues for the management of diabetes mellitus: a meta-analysis. CMAJ 2009; 180 (4): 385–397. EK Ia

    Google Scholar 

  39. Monami M, Marchionni N, Mannucci E. Long-acting insulin analogues vs. NPH human insulin in type 1 diabetes. A meta-analysis. Diabetes Obes Metab 2009; 11 (4): 372–378. EK Ia

    CAS  Google Scholar 

  40. Mullins P, Sharplin P, Yki-Jarvinen H et al. Negative binomial metaregression analysis of combined glycosylated hemoglobin and hypoglycemia outcomes across eleven Phase III and IV studies of insulin glargine compared with neutral protamine Hagedorn insulin in type 1 and type 2 diabetes mellitus. Clin Ther 2007; 29 (8): 1607–1619. EK Ia

    CAS  Google Scholar 

  41. Ashwell SG, Bradley C, Stephens JW et al. Treatment satisfaction and quality of life with insulin glargine plus insulin lispro compared with NPH insulin plus unmodified human insulin in individuals with type 1 diabetes. Diabetes Care 2008; 31 (6): 1112–1117. EK Ib

    CAS  Google Scholar 

  42. Hermansen K, Fontaine P, Kukolja KK et al. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes. Diabetologia 2004; 47 (4): 622–629. EK Ib

    Article  CAS  Google Scholar 

  43. Bühn S, Breuing J, Mathes T et al. Evidenzbericht zu ausgewählten Rechercheaufträgen im Rahmen der S3-Leitlinie „Therapie des Typ-1-Diabetes“. Witten/Herdecke: IFOM – Institut für Forschung in der Operativen Medizin (Universität Witten/Herdecke). 2016

  44. Fullerton B, Siebenhofer A, Jeitler K et al. Short-acting insulin analogues versus regular human insulin for adults with type 1 diabetes mellitus. Cochrane Database Syst Rev 2016; (6): CD012161. https://doi.org/10.1002/14651858.CD012161. EK Ia/LoE 1++

    Article  Google Scholar 

  45. Vardi M, Jacobson E, Nini A et al. Intermediate acting versus long acting insulin for type 1 diabetes mellitus. Cochrane Database Syst Rev 2008; (3): CD006297. EK Ia/LoE 1+

    Google Scholar 

  46. Retnakaran R, Hochman J, DeVries JH et al. Continuous subcutaneous insulin infusion versus multiple daily injections: the impact of baseline A1c. Diabetes Care 2004; 27 (11): 2590–2596. EK Ia

    CAS  Google Scholar 

  47. Fatourechi MM, Kudva YC, Murad MH et al. Clinical review: Hypoglycemia with intensive insulin therapy: a systematic review and meta-analyses of randomized trials of continuous subcutaneous insulin infusion versus multiple daily injections. J Clin Endocrinol Metab 2009; 94 (3):729–740. EK Ia

    Article  CAS  Google Scholar 

  48. Jeitler K, Horvath K, Berghold A et al. Continuous subcutaneous insulin infusion versus multiple daily insulin injections in patients with diabetes mellitus: systematic review and meta-analysis. Diabetologia 2008; 51 (6): 941–951. EK Ia

    CAS  Google Scholar 

  49. Pickup JC, Sutton AJ. Severe hypoglycaemia and glycaemic control in Type 1 diabetes: meta-analysis of multiple daily insulin injections compared with continuous subcutaneous insulin infusion. Diabet Med 2008; 25 (7): 765–774. EK IIb

    CAS  Google Scholar 

  50. Bolli GB, Kerr D, Thomas R et al. Comparison of a multiple daily insulin injection regimen (basal once-daily glargine plus mealtime lispro) and continuous subcutaneous insulin infusion (lispro) in type 1 diabetes: a randomized open parallel multicenter study. Diabetes Care 2009; 32 (7): 1170–1176. EK Ib

    Article  CAS  Google Scholar 

  51. Steineck I, Cederholm J, Eliasson B et al. Insulin pump therapy, multiple daily injections, and cardiovascular mortality in 18168 people with type 1 diabetes: observational study. BMJ 2015; 350: h3234. EK IIb

    Article  Google Scholar 

  52. Barnard KD, Lloyd CE, Skinner TC. Systematic literature review: quality of life associated with insulin pump use in Type 1 diabetes. Diabet Med 2007; 24 (6): 607–617. EK Ia

    CAS  Google Scholar 

  53. Hoogma RP, Hammond PJ, Gomis R et al. Comparison of the effects of continuous subcutaneous insulin infusion (CSII) and NPH-based multiple daily insulin injections (MDI) on glycaemic control and quality of life: results of the 5‑nations trial. Diabet Med 2006; 23 (2): 141–147. EK Ib

    CAS  Google Scholar 

  54. Mukhopadhyay A, Farrell T, Fraser RB et al. Continuous subcutaneous insulin infusion vs intensive conventional insulin therapy in pregnant diabetic women: a systematic review and metaanalysis of randomized, controlled trials. Am J Obstet Gynecol 2007; 197 (5): 447–456. EK Ia

    Article  CAS  Google Scholar 

  55. Farrar D, Tuffnell DJ, West J. Continuous subcutaneous insulin infusion versus multiple daily injections of insulin for pregnant women with diabetes. Cochrane Database Syst Rev 2007; 3: CD005542. EK Ia

    Google Scholar 

  56. Chen R, Ben-Haroush A, Weismann-Brenner A et al. Level of glycemic control and pregnancy outcome in type 1 diabetes: a comparison between multiple daily insulin injections and continuous subcutaneous insulin infusions. Am J Obstet Gynecol 2007; 197 (4): 404–405. EK IIb

    Article  Google Scholar 

  57. Cypryk K, Kosinski M, Kaminska P et al. Diabetes control and pregnancy outcomes in women with type 1 diabetes treated during pregnancy with continuous subcutaneous insulin infusion or multiple daily insulin injections. Pol Arch Med Wewn 2008; 118 (6): 339–344. EK IIb

    CAS  Google Scholar 

  58. Gimenez M, Conget I, Nicolau J et al. Outcome of pregnancy in women with type 1 diabetes intensively treated with continuous subcutaneous insulin infusion or conventional therapy. A case-control study. Acta Diabetol 2007; 44 (1): 34–37. EK III

    Article  CAS  Google Scholar 

  59. Alto WA, Meyer D, Schneid J et al. Assuring the accuracy of home glucose monitoring. J Am Board Fam Pract 2002; 15 (1): 1–6. EK III

    Google Scholar 

  60. Saudek CD, Derr RL, Kalyani RR. Assessing glycemia in diabetes using self-monitoring blood glucose and hemoglobin A1c. JAMA 2006; 295 (14): 1688–1697. EK IV

    Article  CAS  Google Scholar 

  61. Bundesärztekammer, Kassenärztliche Bundesvereinigung, Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften. Nationale VersorgungsLeitlinie Diabetes – Strukturierte Schulungsprogramme – Langfassung, 1. Auflage. Version 4. Im Internet: http://www.dm-schulung.versorgungsleitlinien.de; Stand: 4. Nov. 2017. EK IV

  62. Kulzer B, Albus C, Herpertz S et al. Psychosoziales und Diabetes (Teil 1). Diabetologie und Stoffwechsel 2013; a 8 (3): 198–242. https://doi.org/10.1055/s-0033-1335785. EK IV

    Article  Google Scholar 

  63. Kulzer B, Albus C, Herpertz S et al. Psychosoziales und Diabetes (Teil 2). Diabetologie und Stoffwechsel 2013; b 8 (4): 292–324. https://doi.org/10.1055/s-0033-1335889. EK IV

    Article  Google Scholar 

  64. Hermanns N, Kulzer B, Krichbaum M. Problemspezifische Patientenschulung. Übersicht zu einem wesentlichen Bestandteil der Diabetestherapie. Diabetologe 2008; 4 (5): 361–367. EK III

    Article  Google Scholar 

  65. American Diabetes Association. 14. Diabetes Care in the Hospital. Diabetes Care 2017; 40 (Suppl. 1): S120–S127. https://doi.org/10.2337/dc17-S017. EK IV

    Article  Google Scholar 

  66. Chen HS, Wu TE, Jap TS et al. Effects of health education on glycemic control during holiday time in patients with type 2 diabetes mellitus. Am J Manag Care 2008; 14 (1): 45–51. EK Ib/LoE

    PubMed  Google Scholar 

  67. Canadian Diabetes Association. 2013 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. Im Internet: http://guidelines.diabetes.ca/app_themes/cdacpg/resources/cpg_2013_full_en.pdf; Stand: 23. Juli 2017. EK IV

  68. Graveling AJ, Frier BM. Hypoglycaemia: an overview. Prim Care Diabetes 2009; 3 (3): 131–139. EK III

    Article  Google Scholar 

  69. Cryer PE. The barrier of hypoglycemia in diabetes. Diabetes 2008; 57 (12): 3169–3176. EK III

    CAS  Google Scholar 

  70. Deary IJ, Hepburn DA, MacLeod KM et al. Partitioning the symptoms of hypoglycaemia using multi-sample confirmatory factor analysis. Diabetologia 1993; 36 (8): 771–777. EK III/LoE 3

    Article  CAS  Google Scholar 

  71. McAulay V, Deary IJ, Frier BM. Symptoms of hypoglycaemia in people with diabetes. Diabet Med 2001; 18 (9): 690–705. EK III

    CAS  Google Scholar 

  72. Haak T, Kellerer M (2009) Diagnostik, Therapie und Verlaufskontrolle des Diabetes mellitus im Kindes- und Jugendalter. Mainz: Kirchheim. Deutsche Diabetes Gesellschaft, EK IV

    Google Scholar 

  73. Kitabchi AE, Umpierrez GE, Murphy MB et al. Hyperglycemic crises in adult patients with diabetes: a consensus statement from the American Diabetes Association. Diabetes Care 2006; 29 (12): 2739–2748. EK IV

    CAS  Google Scholar 

  74. Kitabchi AE, Umpierrez GE, Miles JM et al. Hyperglycemic crises in adult patients with diabetes. Diabetes Care 2009; 32 (7): 1335–1343. EK IV

    CAS  Google Scholar 

  75. Bull SV, Douglas IS, Foster M et al. Mandatory protocol for treating adult patients with diabetic ketoacidosis decreases intensive care unit and hospital lengths of stay: results of a nonrandomized trial. Crit Care Med 2007; 35 (1): 41–46. EK IIb

    Google Scholar 

  76. Joint British Diabetes Societies for inpatient care. The Management of Diabetic Ketoacidosis in Adults. Second Edition Update: September 2013. Im Internet: http://www.diabetologists-abcd.org.uk/JBDS/JBDS_IP_DKA_Adults_Revised.pdf; Stand: 23. Sept. 2017. EK IV

  77. Bundesärztekammer, Kassenärztliche Bundesvereinigung, Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften. Nationale VersorgungsLeitlinie Typ-2-Diabetes – Nierenerkrankungen bei Diabetes im Erwachsenenalter. Version Konsultation 1.0; 2010. EK IV

  78. Bundesärztekammer, Kassenärztliche Bundesvereinigung, Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften. Nationale VersorgungsLeitlinie Prävention und Therapie von Netzhautkomplikationen bei Diabetes – Langfassung, 2. Auflage. Version 2. Im Internet: http://www.netzhautkomplikationen.versorgungsleitlinien.de; Stand: 19. Okt. 2017. EK IV

  79. Bundesärztekammer, Kassenärztliche Bundesvereinigung, Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (2010) Nationale VersorgungsLeitlinie Neuropathie bei Diabetes im Erwachsenenalter. Ek Iv

  80. Bundesärztekammer, Kassenärztliche Bundesvereinigung, Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften. Nationale VersorgungsLeitlinie Typ-2-Diabetes – Präventions- und Behandlungsstrategien für Fuβkomplikationen. Version 2.8; 2006. EK IV

  81. Bundesärztekammer, Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften, Kassenärztliche Bundesvereinigung (2010) Nationale VersorgungsLeitlinie Nierenerkrankungen bei Diabetes im Erwachsenenalter. Ek Iv

Download references

Author information

Authors and Affiliations

  1. Diabetes-Klinik Bad Mergentheim, Theodor-Klotzbücher-Str. 12, 97980, Bad Mergentheim, Deutschland

    Thomas Haak

  2. Diabetesschwerpunktpraxis Esslingen, Esslingen, Deutschland

    Stefan Gölz

  3. Innere Medizin IV, Medizinische Klinik, Universitätsklinikum Tübingen, Tübingen, Deutschland

    Andreas Fritsche

  4. Diabeteszentrum am Marienplatz, München, Deutschland

    Martin Füchtenbusch

  5. Isarklinikum, München, Deutschland

    Thorsten Siegmund

  6. Birkenfeld, Deutschland

    Elisabeth Schnellbächer

  7. Medizinische Universitätsklinik I – Allgemeine Innere Medizin, Endokrinologie und Diabetologie, Gastroenterologie und Hepatologie, Berufsgenossenschaftliches Universitätsklinikum, Bergmannsheil, Deutschland

    Harald H. Klein

  8. prima-diab Praxis Dres. Uebel/Nittka/Mayer/Merkle, Ittlingen, Deutschland

    Til Uebel

  9. Eschweiler, Deutschland

    Diana Droßel

Authors
  1. Thomas Haak
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stefan Gölz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Andreas Fritsche
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Martin Füchtenbusch
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Thorsten Siegmund
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Elisabeth Schnellbächer
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Harald H. Klein
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Til Uebel
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Diana Droßel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Thomas Haak.

Ethics declarations

Interessenkonflikt

Eine Übersicht über die Interessenkonflikte findet sich im Leitlinienreport unter: https://www.awmf.org/uploads/tx_szleitlinien/057-013m_S3-Therapie-Typ-1-Diabetes_2018-04.pdf

Additional information

Dieser Beitrag wurde erstpubliziert in Diabetologie und Stoffwechsel (2018) 13 (Suppl 2):S120–S130, https://doi.org/10.1055/a-0598-6528. Nachdruck mit freundl. Genehmigung von Georg Thieme Verlag KG. Die Urheberrechte liegen bei den Autoren.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Haak, T., Gölz, S., Fritsche, A. et al. Therapie des Typ-1-Diabetes. Diabetologe 15, 135–145 (2019). https://doi.org/10.1007/s11428-019-0458-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11428-019-0458-8

Search

Navigation